Save time and jump to the most important pieces.
6-K - PAINREFORM LTD. (0001801834) (Filer)
6-K - PAINREFORM LTD. (0001801834) (Filer)
6-K - PAINREFORM LTD. (0001801834) (Filer)
TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research ("Lotus"), for the Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. Initial analysis of the topline data indicates that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery. These findings underscore PRF-
This notification has no immediate effect on the listing or trading of PainReform's ordinary shares on the Nasdaq Capital Market TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has received a notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it no longer satisfied the minimum $2.5 million stockholders' equity requirement for continued listing on Nasdaq set forth in Nasdaq Listing Rule 5550(b)(1) (the "Minimum Equity Rule
TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive findings regarding the compatibility of sutures in human clinical trials of its lead product, PRF-110. PRF-110 is designed to provide extended, non-opiate, post-surgical pain relief. The Company conducted comprehensive in vitro studies to assess the impact of PRF-110 on both non-absorbable and resorbable sutures. Given that suture materials are often in proximity to the PRF-110 oily solution following surgery, it was critical to evaluate whethe
HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update. Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri
HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing
SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)
SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)
SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)
- SEC Filing
Maxim Group analyst Naz Rahman reiterates PainReform (NASDAQ:PRFX) with a Buy and maintains $2 price target.